Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04211714 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
A Phase 1 study of Bone Marrow Failure and Telomere Shortening, sponsored by Elixirgen Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04211714 is a Phase 1 study of Bone Marrow Failure and Telomere Shortening that is active but no longer recruiting, run by Elixirgen Therapeutics. The registered enrollment target is 12 participants, below the 28-participant average among 5 other Bone Marrow Failure trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04211714, a Phase 1 study of Bone Marrow Failure and Telomere Shortening, is active but no longer recruiting, sponsored by Elixirgen Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I/II, open label, single center study to assess the safety and tolerability of EXG34217 in bone marrow failure patients with telomere biology disorders.
Conditions Studied
Interventions
- BIOLOGICAL EXG34217
Study Locations (1)
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2027-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04211714
The ClinicalTrials.gov registry entry for NCT04211714 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 28-participant average among 5 other Bone Marrow Failure trials with a reported enrollment target (57% lower). The listed sponsor is Elixirgen Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bone Marrow Failure appearing as the primary indexed condition, and to 1 intervention - of which EXG34217 is the first listed.
NCT04211714 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04211714 about?
NCT04211714 is a clinical study titled "Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure". This is a Phase I/II, open label, single center study to assess the safety and tolerability of EXG34217 in bone marrow failure patients with telomere biology disorders.
What is the current status of trial NCT04211714?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-04-08. Estimated completion is 2027-10-08.
What conditions does trial NCT04211714 study?
This clinical trial studies the following conditions: Bone Marrow Failure, Telomere Shortening.
What interventions are being tested in trial NCT04211714?
The interventions under investigation include: EXG34217 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04211714?
This trial is sponsored by Elixirgen Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04211714 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Marrow Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
RECRUITING · Phase 2
-
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.